180 related articles for article (PubMed ID: 1717120)
1. Forskolin and phosphodiesterase inhibitors release adenosine but inhibit morphine-evoked release of adenosine from spinal cord synaptosomes.
Nicholson D; White TD; Sawynok J
Can J Physiol Pharmacol; 1991 Jun; 69(6):877-85. PubMed ID: 1717120
[TBL] [Abstract][Full Text] [Related]
2. Effects of forskolin and phosphodiesterase inhibitors on spinal antinociception by morphine.
Nicholson D; Reid A; Sawynok J
Pharmacol Biochem Behav; 1991 Apr; 38(4):753-8. PubMed ID: 1714608
[TBL] [Abstract][Full Text] [Related]
3. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase.
Wright CD; Kuipers PJ; Kobylarz-Singer D; Devall LJ; Klinkefus BA; Weishaar RE
Biochem Pharmacol; 1990 Aug; 40(4):699-707. PubMed ID: 1696820
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
5. Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
Ransjö M; Fredholm BB; Lerner UH
Bone Miner; 1988 Jan; 3(3):225-34. PubMed ID: 2462948
[TBL] [Abstract][Full Text] [Related]
6. Potentiation by forskolin of both SNP- and ANP-stimulated cyclic GMP accumulation in porcine isolated palmar lateral vein.
Wright IK; Amirchetty-Rao S; Kendall DA
Br J Pharmacol; 1994 Aug; 112(4):1146-50. PubMed ID: 7524992
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the effects of cyclic nucleotide phosphodiesterase inhibitors on bone resorption and cyclic AMP formation in vitro.
Lerner U; Ransjö M; Fredholm BB
Biochem Pharmacol; 1986 Dec; 35(23):4177-89. PubMed ID: 2431692
[TBL] [Abstract][Full Text] [Related]
8. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
9. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
10. Role of adenylate cyclase in presynaptic alpha 2-adrenoceptor- and mu-opioid receptor-mediated inhibition of [3H]noradrenaline release from rat brain cortex slices.
Schoffelmeer AN; Wierenga EA; Mulder AH
J Neurochem; 1986 Jun; 46(6):1711-7. PubMed ID: 2422322
[TBL] [Abstract][Full Text] [Related]
11. Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.
Wachtel H
J Neural Transm; 1983; 56(2-3):139-52. PubMed ID: 6190991
[TBL] [Abstract][Full Text] [Related]
12. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603
[TBL] [Abstract][Full Text] [Related]
13. Existence of rolipram-sensitive phosphodiesterase in rat megakaryocyte.
Akaike N; Uneyama H; Kawa K; Yamashita Y
Br J Pharmacol; 1993 Aug; 109(4):1020-3. PubMed ID: 7691362
[TBL] [Abstract][Full Text] [Related]
14. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
15. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function.
Weston MC; Anderson N; Peachell PT
Br J Pharmacol; 1997 May; 121(2):287-95. PubMed ID: 9154339
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of phosphodiesterase inhibitors on accumulation of cyclic AMP in isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Biochem Pharmacol; 1995 Feb; 49(4):441-52. PubMed ID: 7872950
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effect of isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels in SH-SY5Y neuroblastoma cells.
Morgan AJ; Murray KJ; Challiss RA
Biochem Pharmacol; 1993 Jun; 45(12):2373-80. PubMed ID: 7687130
[TBL] [Abstract][Full Text] [Related]
18. The stimulatory action of phosphodiesterase inhibitors on the flexor reflex of the hind limb in the spinal rat.
Przegaliński E; Rawłów A
J Neural Transm; 1982; 55(1):9-17. PubMed ID: 6182270
[TBL] [Abstract][Full Text] [Related]
19. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
20. Modulation of carbachol-induced inositol phosphate formation in bovine tracheal smooth muscle by cyclic AMP phosphodiesterase inhibitors.
Hall IP; Donaldson J; Hill SJ
Biochem Pharmacol; 1990 Apr; 39(8):1357-63. PubMed ID: 1690998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
